How were TapImmune's earnings last quarter?

TapImmune, Inc. (NASDAQ:TPIV) posted its quarterly earnings results on Thursday, August, 9th. The company reported ($0.41) EPS for the quarter. The company earned $0.21 million during the quarter.

What other stocks do shareholders of TapImmune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TapImmune investors own include Verastem (VSTM) , Viking Therapeutics (VKTX) , Portola Pharmaceuticals (PTLA) , Rigel Pharmaceuticals (RIGL) , Coherus BioSciences (CHRS) , Fate Therapeutics (FATE) , Galectin Therapeutics (GALT) , Cellectis (CLLS) , CRISPR Therapeutics (CRSP) and Dynavax Technologies (DVAX) .

NASDAQ:TPIV

TapImmune (TPIV) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free TPIV Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $8.01
▼
$8.40
50-Day Range: $8.34
▼
$8.34
52-Week Range: $2.58
▼
$13.55

Volume: 100,653 shs
Average Volume: 235,808 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get TapImmune alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About TapImmune

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Ad Crypto 101 Media

SHOCKING Crypto Leak…

Claim your free seat by clicking here now.

TPIV Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive TPIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TapImmune and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/09/2018
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TPIV
CUSIP: N/A
CIK: 1094038
Web: www.tapimmune.com
Phone: (713) 400-6400
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Optionable
Beta: N/A

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Peter L. Hoang
President, Chief Executive Officer & Director
Anthony H. Kim
Chief Financial Officer
Ann M. Leen
Chief Scientific Officer
Mythili Koneru
Chief Medical Officer
Gerald Garrett
Vice President-Clinical Operations

Key Competitors

View All Competitors

TPIV Stock Analysis - Frequently Asked Questions

How were TapImmune's earnings last quarter?: TapImmune, Inc. (NASDAQ:TPIV) posted its quarterly earnings results on Thursday, August, 9th. The company reported ($0.41) EPS for the quarter. The company earned $0.21 million during the quarter.
What other stocks do shareholders of TapImmune own?: Based on aggregate information from My MarketBeat watchlists, some companies that other TapImmune investors own include Verastem (VSTM), Viking Therapeutics (VKTX), Portola Pharmaceuticals (PTLA), Rigel Pharmaceuticals (RIGL), Coherus BioSciences (CHRS), Fate Therapeutics (FATE), Galectin Therapeutics (GALT), Cellectis (CLLS), CRISPR Therapeutics (CRSP) and Dynavax Technologies (DVAX).

This page (NASDAQ:TPIV) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

TapImmune (TPIV) Stock Price, News & Analysis

About TapImmune

TPIV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

TPIV Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info